Table 1. Characteristics, treatment and outcome of Influenza A(H1N1)pdm09-infected CF patients.

Country	Inf A(H1N1)pdm09 infection in CF patients			Characteristics of CF patients infected with Inf A(H1N1)pdm09 (%)				Treatment (%)	Outcome (%)			Conclusion / Recommendation	Ref
	N 1	Age 2	Incidence* (%)	P. aerug. // B. cepacia coinfection	Pancreatic Insufficiency	FEV1 pred3	Vacc	Oseltamivir // Antibiotics	Hospital admission	ICU 4 or ventilation	CFR 5
Europe#	110	13	2.3*	n.r.	84	69	8.8	81 // 66	48	5.4	2.7	awareness, infection control, vaccination campaign	[39]
Italy#	68	15	53**	48.5 // 8.8	89.7	53	13.2	82 // 68	69	1.5 ventilation 13.2 on oxygen	4.4	annual vaccination in adult CF patients	[41]
Australia	11	22	4.4*	100 // 1	n.r.	66	n.av.	100 // 75	63	n.r.	n.r.	prompt commencement of oseltamivir and antibiotic therapy	[42]
UK	13	22	4*	100 // n.r.	n.r.	51.4	n.r.	100 // 100	69	0	n.r.	generally mild illness in CF, potentially more virulent pandemic in the future	[40]

¹Number of Influenza A(H1N1)pdm09 positive CF patients

²Mean age (years)

³Mean of all CF patients studied

⁴Intensive care unit

⁵Case fatality rate

^#multicenter surveys; *incidence of Inf A(H1N1)pdm09 infections in CF patients **incidence of Inf A(H1N1)pdm09 infections relating to CF patients with influenza-like illness (ILI); n.r. – not reported; Vacc – Vaccination coverage; P. aerug.  =  Pseudomonas aeruginosa; B. cepacia  =  Burkholderia cepacia.